开源证券给予佐力药业“买入”评级，公司信息更新报告：拟收购未来医药资产组丰富产品结构，营销协同发展

Group 1 - The core viewpoint of the report is that Zhaoli Pharmaceutical (300181.SZ) is rated as "Buy" due to the large market potential for various trace element injection solutions, supported by "medical insurance + centralized procurement" which aids in sales growth [1] - The company has a rich product structure and is expected to benefit from marketing synergies [1] Group 2 - The report highlights the significant annual sales of 300 million yuan for the "youthful needle" product, raising concerns among investors regarding the legitimacy of associated parties and the financial situation of Jiangsu Wuzhong, which is facing delisting [1]